Literature DB >> 16000631

A highly specific inhibitor of matrix metalloproteinase-9 rescues laminin from proteolysis and neurons from apoptosis in transient focal cerebral ischemia.

Zezong Gu1, Jiankun Cui, Stephen Brown, Rafael Fridman, Shahriar Mobashery, Alex Y Strongin, Stuart A Lipton.   

Abstract

Neuronal cell death occurs during many neurodegenerative disorders and stroke. The aberrant, excessive activity of matrix metalloproteinases (MMPs), especially MMP-9, contributes directly to neuron apoptosis and brain damage (Rosenberg et al., 1996; Asahi et al., 2001; Gu et al., 2002; Horstmann et al., 2003). We determined that MMP-9 degrades the extracellular matrix protein laminin and that this degradation induces neuronal apoptosis in a transient focal cerebral ischemia model in mice. We also determined that the highly specific thiirane gelatinase inhibitor SB-3CT blocks MMP-9 activity, including MMP-9-mediated laminin cleavage, thus rescuing neurons from apoptosis. We conclude that MMP-9 is a highly promising drug target and that SB-3CT derivatives have significant therapeutic potential in stroke patients.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16000631      PMCID: PMC6725288          DOI: 10.1523/JNEUROSCI.1563-05.2005

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.709


  26 in total

Review 1.  Gelatinase B: a tuner and amplifier of immune functions.

Authors:  G Opdenakker; P E Van den Steen; J Van Damme
Journal:  Trends Immunol       Date:  2001-10       Impact factor: 16.687

2.  X-ray absorption studies of human matrix metalloproteinase-2 (MMP-2) bound to a highly selective mechanism-based inhibitor. comparison with the latent and active forms of the enzyme.

Authors:  O Kleifeld; L P Kotra; D C Gervasi; S Brown; M M Bernardo; R Fridman; S Mobashery; I Sagi
Journal:  J Biol Chem       Date:  2001-01-30       Impact factor: 5.157

3.  Metalloproteinase inhibition reduces thrombolytic (tissue plasminogen activator)-induced hemorrhage after thromboembolic stroke.

Authors:  P A Lapchak; D F Chapman; J A Zivin
Journal:  Stroke       Date:  2000-12       Impact factor: 7.914

4.  Matrix metalloproteinases increase very early during experimental focal cerebral ischemia.

Authors:  J H Heo; J Lucero; T Abumiya; J A Koziol; B R Copeland; G J del Zoppo
Journal:  J Cereb Blood Flow Metab       Date:  1999-06       Impact factor: 6.200

5.  Effects of matrix metalloproteinase-9 gene knock-out on the proteolysis of blood-brain barrier and white matter components after cerebral ischemia.

Authors:  M Asahi; X Wang; T Mori; T Sumii; J C Jung; M A Moskowitz; M E Fini; E H Lo
Journal:  J Neurosci       Date:  2001-10-01       Impact factor: 6.167

Review 6.  Matrix metalloproteinase inhibitors and cancer: trials and tribulations.

Authors:  Lisa M Coussens; Barbara Fingleton; Lynn M Matrisian
Journal:  Science       Date:  2002-03-29       Impact factor: 47.728

7.  Role for matrix metalloproteinase 9 after focal cerebral ischemia: effects of gene knockout and enzyme inhibition with BB-94.

Authors:  M Asahi; K Asahi; J C Jung; G J del Zoppo; M E Fini; E H Lo
Journal:  J Cereb Blood Flow Metab       Date:  2000-12       Impact factor: 6.200

Review 8.  Strategies for MMP inhibition in cancer: innovations for the post-trial era.

Authors:  Christopher Mark Overall; Carlos López-Otín
Journal:  Nat Rev Cancer       Date:  2002-09       Impact factor: 60.716

9.  S-nitrosylation of matrix metalloproteinases: signaling pathway to neuronal cell death.

Authors:  Zezong Gu; Marcus Kaul; Boxu Yan; Steven J Kridel; Jiankun Cui; Alex Strongin; Jeffrey W Smith; Robert C Liddington; Stuart A Lipton
Journal:  Science       Date:  2002-08-16       Impact factor: 47.728

Review 10.  Metalloproteinases in biology and pathology of the nervous system.

Authors:  V W Yong; C Power; P Forsyth; D R Edwards
Journal:  Nat Rev Neurosci       Date:  2001-07       Impact factor: 34.870

View more
  166 in total

Review 1.  Fetal hypoxia and programming of matrix metalloproteinases.

Authors:  Wenni Tong; Lubo Zhang
Journal:  Drug Discov Today       Date:  2011-09-18       Impact factor: 7.851

Review 2.  Matrix metalloproteinase inhibitors as investigative tools in the pathogenesis and management of vascular disease.

Authors:  Mina M Benjamin; Raouf A Khalil
Journal:  Exp Suppl       Date:  2012

Review 3.  Ectoplasmic specialization: a friend or a foe of spermatogenesis?

Authors:  Helen H N Yan; Dolores D Mruk; Will M Lee; C Yan Cheng
Journal:  Bioessays       Date:  2007-01       Impact factor: 4.345

Review 4.  Matrix metalloproteinases and the regulation of tissue remodelling.

Authors:  Andrea Page-McCaw; Andrew J Ewald; Zena Werb
Journal:  Nat Rev Mol Cell Biol       Date:  2007-03       Impact factor: 94.444

5.  Role of matrix metalloproteinases in the acquisition and reconsolidation of cocaine-induced conditioned place preference.

Authors:  Travis E Brown; Melissa R Forquer; Davelle L Cocking; Heiko T Jansen; Joseph W Harding; Barbara A Sorg
Journal:  Learn Mem       Date:  2007-03-09       Impact factor: 2.460

6.  Carnosic acid, a catechol-type electrophilic compound, protects neurons both in vitro and in vivo through activation of the Keap1/Nrf2 pathway via S-alkylation of targeted cysteines on Keap1.

Authors:  Takumi Satoh; Kunio Kosaka; Ken Itoh; Akira Kobayashi; Masayuki Yamamoto; Yosuke Shimojo; Chieko Kitajima; Jiankun Cui; Joshua Kamins; Shu-ichi Okamoto; Masanori Izumi; Takuji Shirasawa; Stuart A Lipton
Journal:  J Neurochem       Date:  2007-11-06       Impact factor: 5.372

7.  Tumor necrosis factor-related weak inducer of apoptosis augments matrix metalloproteinase 9 (MMP-9) production in skeletal muscle through the activation of nuclear factor-kappaB-inducing kinase and p38 mitogen-activated protein kinase: a potential role of MMP-9 in myopathy.

Authors:  Hong Li; Ashwani Mittal; Pradyut K Paul; Mukesh Kumar; Daya S Srivastava; Suresh C Tyagi; Ashok Kumar
Journal:  J Biol Chem       Date:  2008-12-11       Impact factor: 5.157

8.  MiR-539 Targets MMP-9 to Regulate the Permeability of Blood-Brain Barrier in Ischemia/Reperfusion Injury of Brain.

Authors:  Feng Fan; Jiao Yang; Yuanjie Xu; Sheng Guan
Journal:  Neurochem Res       Date:  2018-10-01       Impact factor: 3.996

Review 9.  Matrix metalloproteinases as therapeutic targets for stroke.

Authors:  Yi Yang; Gary A Rosenberg
Journal:  Brain Res       Date:  2015-04-25       Impact factor: 3.252

10.  MMPs initiate Schwann cell-mediated MBP degradation and mechanical nociception after nerve damage.

Authors:  Hideo Kobayashi; Sharmila Chattopadhyay; Kinshi Kato; Jennifer Dolkas; Shin-Ichi Kikuchi; Robert R Myers; Veronica I Shubayev
Journal:  Mol Cell Neurosci       Date:  2008-09-05       Impact factor: 4.314

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.